Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
BackgroundThe aggressive proliferation and spread of breast cancer contributes to a dismal clinical outcome. The present study was to investigate the function and underlying mechanism of the long non-coding RNA (lncRNA) PGM5-AS1 in the modulation of breast cancer.MethodsQuantitative real time-polymerase chain reaction was utilized to assess the levels of PGM5-AS1 and miR-18a-3p. The prognostic significance was evaluated through Kaplan-Meier survival analysis and multivariate Cox regression analysis. Cell viability in breast cancer cells was measured utilizing a cell counting kit-8 kit. Cell migration and invasion were investigated using a transwell assay. The targeted regulatory interaction between PGM5-AS1, miR-18a-3p, and TGFBR3 was validated via dual luciferase reporter gene assay.ResultLevels of PGM5-AS1 were low in both breast tissue and cancer cell lines. This reduction in expression was linked to various clinical characteristics and a reduced overall survival rate in breast cancer patients. Upregulation of PGM5-AS1 expression noticeably inhibited proliferation, migration, and invasion in breast cancer cells. PGM5-AS1 regulated breast cancer development by controlling the miR-18a-3p/TGFBR3 axis.ConclusionThe lncRNA PGM5-AS1/miR-18a-3p/TGFBR3 axis is considered a potential genetic target for the development of breast cancer treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03936155251325846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-help management of side effects in female cancer patients -analysis of the forum of the Women's Self-help Association against cancer.
BMC Cancer
September 2025
Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, Jena, 07747, Germany.
Long non-coding RNA STMN1P2 promotes breast cancer doxorubicin resistance by inhibiting pyroptosis through the hnRNPU-EZH2-TARF6-MALT1-caspase-1 pathway.
Acta Pharmacol Sin
September 2025
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Chemotherapeutic resistance is a significant issue in the treatment of breast cancer, which is related to pyroptosis inhibition. Increasing evidence suggests that long non-coding RNAs (lncRNAs) contribute to tumorigenesis and drug resistance. In this study we investigated the role of the lncRNA STMN1P2 in doxorubicin resistance in breast cancer, as well as its correlation with pyroptosis inhibition.
View Article and Find Full Text PDFGermline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor/normal paired comprehensive genomic profiling test, in Japan.
J Hum Genet
September 2025
Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Comprehensive genomic profiling (CGP) expands treatment options for solid tumor patients and identifies hereditary cancers. However, in Japan, confirmatory tests have been conducted in only 31.6% of patients with presumed germline pathogenic variants (GPVs) detected through tumor-only testing.
View Article and Find Full Text PDFUndescribed Breast Blood Supply from the Brachial Artery: Circumflex Mammary Artery.
Cardiovasc Intervent Radiol
September 2025
The Department of Radiology, Wakayama Medical University, Wakayama, Japan.
Purpose: Recent advancements in medical technologies have made trans-arterial treatment of breast cancer feasible. Consequently, understanding the vascular anatomies of breast cancers and axillary lymph node metastases has become indispensable for sophisticated treatments. The aim of this study was to determine the vascular anatomy of the breast, which is crucial for trans-arterial chemoembolization in patients with breast cancer.
View Article and Find Full Text PDFAuthor Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun
September 2025
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90033, California, USA.